Pharmacy Is Right For Me

JULY 11, 2022

There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! To highlight some of the more unique career settings in the industry, we’re introducing a new page on our website— Novel Pharmacy Practice Settings —where you can explore these unique career pathways. In addition to learning more about unique pathways on our new webpage, we’ll also be featuring pharmacists who work in these unique settings on our blog.

Long-Term Care Facilities 130

Long-Term Care Facilities Independent Pharmacies Community Pharmacies Vaccines 130

Pharmacy Times

JULY 11, 2022

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses how pharmacists can support patients with cancer who have a much higher risk of heart disease.

143

143

PharmaVoice

JULY 11, 2022

Deloitte's senior manager of R&D and regulatory practices explains how technology and strategy must converge to smooth out the bulky drug approval process.

105

105

Pharmacy Times

JULY 11, 2022

Joe Duarte, co-founder and president of ContinuumMD, discusses a program model that allows pharmacies to provide virtual and in-person primary care options for rural communities with health care access challenges.

116

116

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JULY 11, 2022

Annie Kennedy, chief of policy, advocacy, and patient engagement at the EveryLife Foundation for Rare Diseases, tells us why the Foundation sponsored The National Economic Burden of Rare Disease Study, undertaking the challenge of examining the financial impacts of rare diseases. In 2018, the Foundation and its partners elected to perform The National Economic Burden of Rare Disease Study when it recognised that little data existed on who was living with rare diseases and what cost barriers were

Hospitals 98

Hospitals 98

Pharmacy Times

JULY 11, 2022

Emphasizing the accessible nature of pharmacies and why this is essential for patients can help legislators and others understand why changes are necessary.

121

121

Pharmacy Times

JULY 11, 2022

Learning the Pharmacists' Patient Care Process steps and being mindful or internalizing those can help set best practices for pharmacy team members.

Patient Care 123

Patient Care 123

Pharmaceutical Technology

JULY 11, 2022

Research and innovation in supply chain & logistics in the pharmaceutical sector has declined in the last year. The most recent figures show that the number of supply chain and logistics related patent applications in the industry stood at 17 in the three months ending May - down from 21 over the same period in 2021. Figures for patent grants related to supply chain and logistics followed a similar pattern to filings - shrinking from 2 in the three months ending May 2021 to 1 in the same per

98

98

Pharmacy Times

JULY 11, 2022

Patients with refractory chronic migraine experience short- and medium-term pain relief and minimal adverse drug effects from lidocaine infusions.

123

123

PharmaVoice

JULY 11, 2022

Phil Brown, Dermavant’s chief medical officer, discusses VTAMA — the first topical cream approved for psoriasis in 25 years.

98

98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

JULY 11, 2022

Subcutaneous immunotherapy-induced antibodies may serve as a potential allergen-targeted biologics candidate for the treatment of allergic asthma.

122

122

European Pharmaceutical Review

JULY 11, 2022

Headquartered in Lyon, France, Aurobac Therapeutics aims to develop a new precision medicine approach to antibiotic treatment , from diagnosis to cure. The joint-venture is majority-funded by Boehringer Ingelheim (€30 million), with life science company Evotec and diagnostics specialist bioMérieux contributing €5 million each. . ”Antibiotic resistance kills about 1.27 million people globally every year and it has been estimated that by 2050, as many as 10 million worldwide deaths could result fr

78

78

Pharmacy Times

JULY 11, 2022

There is new guidance needed for pediatric immunizations, and pharmacists should be prepared for what's to come.

Immunization 132

Immunization 132

pharmaphorum

JULY 11, 2022

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of Semma in 2019 – because the FDA wanted to see additional data before allowing the dose to be increased.

Immunization 59

Immunization FDA 59

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JULY 11, 2022

The non-estrogen pill was first approved by the FDA in 1973.

FDA 156

FDA 156

Pharmaceutical Technology

JULY 11, 2022

Innoviva has signed a definitive merger agreement for the acquisition of all of the outstanding shares of La Jolla Pharmaceutical Company for $6.23 for each share in cash or an enterprise value of nearly $149m. As per the deal, Innoviva will acquire La Jolla through its wholly-owned subsidiary. La Jolla focuses on marketing innovative treatments that can enhance outcomes in patients with life-threatening diseases.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA 59

Pharmacy Times

JULY 11, 2022

Health Mart also presented the first ever Innovation Award at McKesson ideaShare 2022.

Patient Care 123

Patient Care 123

Pharmaceutical Technology

JULY 11, 2022

The US Food and Drug Administration (FDA) has granted approval for the supplemental Biologics License Application (sBLA) of Horizon Therapeutics for the Krystexxa (pegloticase) injection, given along with methotrexate, to help uncontrolled gout patients attain a complete response to treatment. The label expansion for Krystexxa plus methotrexate is based on the data from the randomised, controlled MIRROR clinical trial in adults with the condition.

FDA 59

FDA Labelling 59

Pharmacy Times

JULY 11, 2022

Lifestyle modifications are the cornerstone of treatment.

130

130

PharmExec

JULY 11, 2022

Generating an actual brainstorm is elusive. Every marketer, strategist, creative person in every industry has probably seen far more of the opposite.

59

59

Pharmacy Times

JULY 11, 2022

Cole McCoy, PharmD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP explain the additional agents being studied as maintenance therapy options.

65

65

PharmExec

JULY 11, 2022

Kenah joins the leadership team with 18 years of program management, marketing, and customer engagement experience in the healthcare industry, including for WebMD and SonderMind.

52

52

Pharmacy Times

JULY 11, 2022

Ofatumumab (Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis.

65

65

PharmExec

JULY 11, 2022

Kobel discusses taking a company public during a challenging time in the market.

81

81

Pharmacy Times

JULY 11, 2022

Harnessing the current momentum and engaging with legislators is crucial for the pharmacy industry to grow and expand.

65

65

NF2 BioSolutions

JULY 11, 2022

When I left school I studied child development, I met with a careers advisor who told me to be a nurse I’d need to go to university. Straight away I said I wasn’t good enough for uni & that was that. Fast forward 15 years & NF2 showed me, my strength & resilience & I decided life was too short not to at least try. Turns out I was good enough, after gaining a 1st class degree, I stepped into my 1st nursing job at Addenbrookes hospital in September 2020 as a Neuro Nurse

Communication 52

Communication Hospitals 52

OctariusRx

JULY 11, 2022

Preview the new medications of 2022, as we reach the halfway point of the year. The U.S. Food and Drug Administration (FDA) is constantly reviewing and approving new medications and the number of medications approved in recent years, has drastically increased. Keeping up with all the changes can be a full-time job. In this post, we look at the most recent approvals to keep you informed and help you keep your patients safe.

FDA 52

FDA 52

Colors Make me Happy

JULY 11, 2022

During the winter break of 2021, I decided to pack my stuff and head for the deep Colombian Amazon Forest. I had been thinking about spending time with the indigenous people of Amazonia for a while and after two years of social isolation, stress, and turmoil, I felt the right time had come. My plane landed in Leticia, the capital of the Amazonas and the southernmost town in Colombia.

Communication 52

Communication 52

Pharmacy Times

JULY 11, 2022

James McCloskey, MD, analyzes result data from the QUAZAR AML-001 trial that focused on oral azacytidine.

65

65

Pharmaceutical Technology

JULY 11, 2022

The proportion of pharmaceutical companies hiring for digital media related positions rose in June 2022 compared with the equivalent month last year, with 49.4% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 41.4% of companies who were hiring for digital media related jobs a year ago and an increase compared to the figure of 43.1% in May 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JULY 11, 2022

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International Society on Thrombosis and Haemostasis (ISTH) congress over the weekend. First up is Alnylam-partnered RNAi candidate fitusiran , an antithrombin-targeting agent in development as a treatment for haemophilia A and B with as few as six injections per year, making it a potential rival to RocheR

FDA 52

FDA 52

Pharmaceutical Technology

JULY 11, 2022

North America extended its dominance for internet of things (IoT) hiring among pharmaceutical industry companies in the three months ending May. The number of roles in North America made up 56.4% of total IoT jobs - up from 55.1% in the same quarter last year. That was followed by Europe, which saw a 1.1 year-on-year percentage point change in IoT roles.

52

52

pharmaphorum

JULY 11, 2022

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible for treatment with the drug. The health technology assessment (HTA) organisation initially recommended Tremfya (guselkumab) as a treatment option for adults with active psoriatic arthritis last year, but limited it to patients with moderate-to-severe psoriasis symptoms.

52

52

Outsourcing Pharma

JULY 11, 2022

In this second of a two-part series, a leader from the CRO discusses the types of technologies supporting DCTs and what might lie on the horizon for the field.

52

52